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http://dx.doi.org/10.1016/j.immuni.2012.05.019The letter by Garcia et al. (2012) suggests
our conclusions that (1) TCRa chain pair-
ing can modify the TCRb chain binding
reaction with MHC and (2) by pairing
with a different TCR Va domain, a TCRb
loop conformation changed and created
an altered pMHC binding mode are not
supported by the data presented in our
recent Immunity article (Stadinski et al.,
2011). Below we summarize the question,
model system, and the findings of the
article to show how we justify these
conclusions.
abTCRs are constructed from a finite
set of V gene segments. Despite the
limited sequence diversity of CDR1 and
CDR2 loops, V(D)J rearrangement and
abTCR chain pairing create receptors
that are specific for a particular class of
MHC or MHC-like ligands. Remarkably,
MHC class-specific TCRs often use the
same residues of CDR1 and CDR2 to
bind different classes of MHC (Marrack
et al., 2008), which raises the following
question: if CDR1 and CDR2 loops are
able to bind all MHC molecules, how do
TCRs distinguish different classes of
MHC ligands?
To study the process of MHC ligand
specification, we studied IAb-3K-reactive
T cells and TCRs isolated from YAe62
TCRb transgenic mice. One set of
TCRs recognized only MHC-II ligands.
The second set cross-reacted with b2m-
dependent MHC-I and MHC-like ligands
including H2-Kb and CD1d. Because all
of the TCRs carried the identical TCRb
chain, changes in the TCR-IAb-3K binding
reaction could be ascribed to modifica-
tions induced by pairing with different
TCRa chains. Garcia et al. (2012) suggest
that we have not shown that TCRa chain
pairing can modify the TCRb binding
reaction with MHC. Our data show that
when the identical TCRb chain is paired
with different TCRa chains, (1) different
IAba-helical residues can be required for
TCRb chain binding, (2) different CDR1b
and CDR2b residues can be required forbinding pMHC, and (3) the CDR3b loop
can have a modified conformation, allow-
ing for the CDR3b loop to create different
contacts with the pMHC complex. Thus,
our experiments showed that TCRb
and IAba side chains were differentially
required by the MHC-specific TCRs for
binding depending on the TCRa chain
utilized.
In previous structures of Vb8.2
TCR:pMHC complexes, the CDR1b N29
and CDR2b Y46, Y48, and E54 residues
(Arden et al., 1995) (N31, Y48, Y50, and
E56 in Garcia et al. [2012]) form a
hydrogen bonding network with the IAa
chain residues K39, Q57, and Q61 (Feng
et al., 2007; Reinherz et al., 1999).
Contacts between these CDR2b and
IAba chain residues occur in the YAe62-
IAb-3K structure as well (Dai et al., 2008),
which led to a hypothesis for the exis-
tence of a conserved, pairwise Vb8.2-IA
interaction motif, termed a ‘‘codon’’
(Feng et al., 2007; Garcia et al., 2009).
These CDR2b residues, most notably
Y46 and Y48, are also important for
thymic selection of T cells carrying the
DO TCRb chain (Scott-Browne et al.,
2009). However, other than a study of
two TCRs binding IAb-3K (of which the
YAe62 TCR was one) (Huseby et al.,
2006), the contribution of the MHC IA
helical residues for binding Vb8.2 TCRs
has not been directly evaluated.
We found that TCRs carrying the
YAe62b chain had variable requirements
for CDR1b, CDR2b, and IAba residues.
The variability was most apparent for the
IAba side chains. The YAe62 TCR and
the J809.B5 TCR each use all six
CDR2b and IAba side chains of the
proposed Vb8.2-IA codon for binding
IAb-3K, and neither require the CDR1b
N29 residue (Figure S1A available online).
The J809.B5 TCR differs from YAe62
mostly in the role of IAba Q61, which is
more important for the J809.B5 TCR
(Q61A completely eliminates binding,
Kd > 250 mM) than for YAe62 TCR (Q61AImmunitychanges Kd from 13 mM to 52 mM). In
contrast to the YAe62 and J809.B5
TCRs, the J809.G3 and J809.H1 TCRs
require different TCRb and IAb side chains
to bind IAb-3K. The J809.G3 TCR uses
CDR1b N29, two of the three CDR2b
side chains, and two of the three IAba
side chains for binding. The J809.H1
TCR uses CDR1b N29 and all three
CDR2b residues, yet it does not require
either IAba Q57 or Q61 for binding. In
addition, the pattern of side chain require-
ments used by the J809.G3 and J809.H1
TCRs indicates that the same TCR
Vb8.2 side chains can be used to bind
IAb-3K differently. For example, the
J809.G3 TCR requires IAba K39, yet
does not require its predicted binding
partner, CDR2b E54, and the J809.H1
TCR requires CDR1b N29, yet does not
require IAba Q61. In Stadinski et al.
(2011), we noted that these data did not
appear to be consistent with predicted
binding patterns of the Vb8.2-IA codon
model. These results argue that Vb8.2
TCRs can use CDR1b and CDR2b
residues to bind IA MHC proteins with
an array of nonconserved interactions,
which can be influenced by the paired
TCR chain.
The TCR-MHC coevolution model
described in the letter by Garcia et al.
(2012) suggests that the Vb8.2 CDR2b
residue Y48 is of central importance and
that evolution has selected for it because
of its ‘‘flexibility,’’ i.e., the ability to make
a variety of chemical bonds. This flexibility
will allow it and other germline-encoded
TCR residues to adopt ‘‘different rotamer’’
and ‘‘different pairings of specific amino
acids’’ when binding MHC ligands. Our
data are consistent with an important
role for CDR2b Y48, which was utilized
by each of the TCRs studied regardless
of whether the MHC IAb aQ57 or aQ61
residue side chains were involved.
Can we conclude that as a result of
pairing with a different TCR Va domain,
a TCRb loop conformation changed and36, June 29, 2012 ª2012 Elsevier Inc. 889
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We show that when the J809.B5 TCR is
bound to IAb-3K, the CDR3b loop has
undergone a conformational change rela-
tive to that same loop in the YAe62 TCR
bound to IAb-3K (Figure S1B). The
YAe62 CDR3b loop (red) kinks sharply,
placing the tight hairpin turn above and
between the IAbb chain helix and the
bound 3K peptide. In contrast, the
J809.B5 CDR3b loop (green) is more
open, kinks less tightly, and extends
much closer toward the IAbb chain. The
conformational change creates additional
TCR-MHC contacts and additional buried
surface area (BSA) involving the peptide
and IAbb chain (see Figure 5 in Stadinski
et al., 2011). Because both complexes
contain the identical TCRb, MHC, and
peptide residues, this clearly demon-
strates that TCRa chain pairings can
result in TCRs in which the CDR3b loop
is in a different conformation.
As noted in Garcia et al. (2012) there is
not a large rmsd between the CDR1b
and CDR2b loops of the J809.B5 and
YAe62 TCRs, relative to other examples
of different TCR Vbs binding different
pMHC complexes. This is not surprising
considering that the J809.B5 and YAe62
using the same CDR1b and CDR2b
sequences are identical, are binding the
same ligand, and use the same CDR2b
and IA side chains for binding. The
J809.B5 TCR-IAb-3K complex does have
a rotamer change at IAbaQ61 allowing for
different interactions with TCRb residues890 Immunity 36, June 29, 2012 ª2012 Elsev(see Figure S5 in Stadinski et al., 2011).
Although the structural changes are small,
they help explain why the J809.B5 TCR
has a large increase in the binding require-
ment for the IAba Q61 side chain. Collec-
tively, the different CDR3b conformations,
the altered TCRb-pMHC contacts and
buried surface area, and the TCRb struc-
tural and energetic changes near the
IAba Q61 residue led us to conclude that
the binding modes of the J809.B5 and
YAe62 TCRb chains were different and
due to pairing with different TCRa chains.
How do TCRs generate self-tolerance
and specificity for unique MHC ligands?
Relative to the self-reactive YAe62 TCR,
the self-tolerant J809.B5 TCR has in-
creased CDR3 contacts and creates
more buried surface with the peptide
and has changed how the TCRb chains
interacts with the pMHC. These differ-
ences are clearly observed in the biophys-
ical data (see Figures 3–6, S3, and S4 in
Stadinski et al., 2011). Although these
overall structural changes may seem
‘‘minor,’’ biologically they represent the
differences between a highly self-reac-
tive, MHC class-cross-reactive TCR and
a self-tolerant, MHC class-specific TCR.
The additional self-tolerant, MHC-specific
TCRs studied in Stadinski et al. (2011)
also showed clear changes in TCR-MHC
interactions and an increased require-
ment for peptide residues. The ability of
abTCR chain pairing to modify TCR inter-
actions with both MHC and peptide
highlights a mechanism whereby T cellier Inc.selection can tailor TCR recognition to
the MHC present in the host.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure
and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2012.05.019.
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